Oncobiologics Founder and CEO, Pankaj Mohan , Ph.D., added, "We are thrilled to have Viropro as an anchor partner. Together we form a fully integrated biopharmaceutical alliance to serve the emerging markets. The combination of a state-of-the-art biologics manufacturing facility and support from the Malaysian Government makes Viropro an ideal partner. This unique partnership allows us to bring together technical expertise and quality oversight from the U.S. with a high capability, low cost biologics operation in Malaysia."
Dato' Dr. Mohd Nazlee Kamal , CEO of Malaysian BiotechCorp, commented, "Malaysia's strategy to become a biotech hub for Asia is rapidly gaining traction, and this Viropro/ Oncobiologics partnership is a significant step in moving this effort forward. BiotechCorp is proud to be part of this collaboration and we look forward to many great developments. This project will attract interest in the biosimilars manufacturing field and will certainly build the confidence of global biotech companies in Malaysian companies as we strive to develop the biomedical sector in the country." Malaysian BiotechCorp is an agency under the Ministry of Science, Technology and Innovation (MOSTI) responsible for executing the objectives of the National Biotechnology Policy (NBP).
Proximare, a strategic advisory firm focused on the life sciences and healthcare industries, acted as advisor for the deal. Financial terms were not disclosed.
About Oncobiologics, Inc.
Oncobiologics is a privately-held biopharmaceutical company developing a pipeli
|SOURCE Oncobiologics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved